New combo therapy hopes to shrink lymphoma tumors
NCT ID NCT05169515
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This early-stage study tests two experimental drug combinations for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to find safe doses and see if the combinations can shrink tumors. About 121 participants will receive either mosunetuzumab or glofitamab together with one or two other drugs (CC-220 and/or CC-99282).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Spedali Civili di Brescia
RECRUITINGBrescia, Lombardy, 25123, Italy
-
Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia
RECRUITINGPisa, Piedmont, 56126, Italy
-
Center Hospital
RECRUITINGRamat Gan, 5262199, Israel
-
Clinica Universidad de Navarra-Madrid
RECRUITINGMadrid, 28027, Spain
-
Hadassah University Hospital - Ein Kerem
RECRUITINGJerusalem, 9112001, Israel
-
Hosp Universitario Salamanca
RECRUITINGSalamanca, 37007, Spain
-
Hospital General Universitario Gregorio Maranon
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitari Vall d Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario La Fe
RECRUITINGValencia, Valencia, 46026, Spain
-
ICO L'Hospitalet
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
IRCCS Azienda Ospedaliero Universitaria di Bologna
RECRUITINGBologna, Emilia-Romagna, 40138, Italy
-
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"
RECRUITINGMeldola, Emilia-Romagna, 47014, Italy
-
Irccs Ospedale San Raffaele
RECRUITINGMilan, Lombardy, 20132, Italy
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
NHS Greater Glasgow and Clyde
RECRUITINGGlasgow, G12 0YN, United Kingdom
-
Nottingham University Hospitals City Campus
RECRUITINGNottingham, NG5 1PB, United Kingdom
-
Oxford University Hospitals NHS Trust - Churchill Hospital
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Rambam Health Care Campus
RECRUITINGHaifa, 3109600, Israel
-
Soroka
RECRUITINGBeersheba, 0084101, Israel
-
Sourasky Medical Center
RECRUITINGTel Aviv, 6423900, Israel
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
-
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
RECRUITINGSan Francisco, California, 94143, United States
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University College London Hospitals
RECRUITINGLondon, W1T 7HA, United Kingdom
-
University of Colorado
RECRUITINGAurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.